Jubilant Therapeutics is gearing up for Phase II and first-in-human trials in 2023 with its pipeline of precision medicines that offer safety and therapeutic advantages in cancer and immunology. The company's drug discovery approach focuses on developing candidates through clinical proof of concept, partnering those assets with companies to advance them through late-stage clinical development and to market. Jubilant's lead program, JBI-802, is an oral inhibitor of coREST implicated in the development of hematological tumors like essential thrombocythemia (ET), certain neuroendocrine tumors, and resistance to immune-checkpoint inhibition. In preclinical testing, JBI-802 showed a favorable safety profile with no effect on red blood cells or anemia.
Precision medicine has revolutionized the way we treat diseases by taking into account individual variability in genes, environment, and lifestyle for each person. Jubilant Therapeutics' focus on precision oncology and immunology represents a promising direction for improving patient outcomes through targeted therapies. Their unique drug discovery approach using the TIBEO discovery engine allows them to identify candidate molecules with enhanced therapeutic indices while also having the ability to penetrate the brain. Jubilant's pipeline includes four advanced clinical and pre